Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL...
22 Décembre 2019 - 11:00PM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative targeted medicines and artificial
intelligence to find, fight and follow cancer, today announced that
it will host a conference call to review the top line results from
the Phase 3 CONDOR trial of PyL™ (18F-DCFPyL) in men with
biochemical recurrence of prostate cancer on Monday, December 23,
2019, at 8:00 a.m. ET. The Company intends to issue a press
release announcing the top line results of the CONDOR trial on the
same day in advance of the conference call.
To participate, please dial (877) 250-8889
(domestic) or (720) 545-0001 (international) and reference
conference ID 9165086. A live webcast will be available in the
Media Center of the Progenics website, www.progenics.com, and a
replay will be available there for two weeks.
About PROGENICSProgenics is an
oncology company focused on the development and commercialization
of innovative targeted medicines and artificial intelligence to
find, fight and follow cancer, including: therapeutic agents
designed to treat cancer (AZEDRA®, 1095, and PSMA TTC);
prostate-specific membrane antigen (“PSMA”) targeted imaging agents
for prostate cancer (PyL™ and 1404); and imaging analysis
technology (aBSI and PSMA AI). Progenics has three commercial
products, AZEDRA, for the treatment of patients with unresectable,
locally advanced or metastatic pheochromocytoma or paraganglioma
(rare neuroendocrine tumors of neural crest origin) who require
systemic anticancer therapy; and oral and subcutaneous formulations
of RELISTOR® (methylnaltrexone bromide) for the treatment of
opioid-induced constipation, which are partnered with Bausch Health
Companies Inc.
Forward Looking StatementsThis
press release contains projections and other “forward-looking
statements” regarding future events. Statements contained in this
communication that refer to Progenics’ estimated or anticipated
future results or other non-historical facts are forward-looking
statements that reflect Progenics’ current perspective of existing
trends and information as of the date of this communication and
include statements regarding Progenics’ strategic and operational
plans and delivering value for shareholders. Forward looking
statements generally will be accompanied by words such as
“anticipate,” “believe,” “plan,” “could,” “should,” “estimate,”
“expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,”
“might,” “will,” “possible,” “potential,” “predict,” “project,” or
other similar words, phrases or expressions. Such statements are
predictions only and are subject to risks and uncertainties that
could cause actual events or results to differ materially. These
risks and uncertainties include, among others: risks associated
with the proposed merger transaction with Lantheus Holdings, Inc.;
market acceptance for approved products; the risk that the
commercial launch of AZEDRA may not meet revenue and income
expectations; the cost, timing and unpredictability of results of
clinical trials and other development activities and
collaborations; the unpredictability of the duration and results of
regulatory review of New Drug Applications (NDA) and
Investigational NDAs; the inherent uncertainty of outcomes in the
intellectual property disputes such as the dispute with the
University of Heidelberg regarding PSMA-617; our ability to
successfully develop and commercialize products that incorporate
licensed intellectual property; the effectiveness of the efforts of
our partners to market and sell products on which we collaborate
and the royalty revenue generated thereby; generic and other
competition; the possible impairment of, inability to obtain and
costs of obtaining intellectual property rights; possible product
safety or efficacy concerns, general business, financial,
regulatory and accounting matters, litigation and other risks; and
risks related to changes in the composition of our Board of
Directors following the delivery of shareholder consents in
response to the recent consent solicitation conducted by one of our
shareholders. More information concerning Progenics and such risks
and uncertainties is available on its website, and in its press
releases and reports it files with the Securities and Exchange
Commission (the “SEC”), including those risk factors included in
its Annual Report on Form 10-K for the year ended December 31,
2018, as updated in its subsequent Quarterly Reports on Form 10-Q.
Progenics is providing the information in this press release as of
its date and, except as expressly required by law, Progenics
disclaims any intent or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this press release. For
more information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company’s SEC filings.(PGNX-F)
ContactMelissa DownsInvestor
Relations(646) 975-2533mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024